Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist Eric Christensen.

Thank you so much for listening today. Go check out real life pharmacology.com.

Snag your free 31 page PDF. It's a study guide on the top 200 drugs. Lots of real life clinical

pearls in there that you absolutely need to know,

as well as lots of things in there that often show up on pharmacology and board exams.

So great resource, great refresher, whether you're practicing professional or you're taking

board exams soon as a student.

All right.

So let's get into the drug of the day today, and that is Lasmidatin.

Brand name of this medication is Rayvow, and this drug is used in the management of acute migraines.

It is not a prophylactic agents.

So with that said, knowing that we use it for acute migraine treatment, this drug is

typically going to be kind of a second or third line agent, and it's

because it's a newer agent at this point. So brand name, very expensive, all that sort of stuff.

Mechanistically, this drug is a little bit different from the triptans.

So it is a 5HT-1F receptor antagonist or serotonin 1F receptor, excuse me, agonist, agonist.

Now, if we compare that and contrast that to triptans,

triptins are 5HT version 1B and 1D agonus.

And the critical difference there and the clinical difference as to why it might make a difference in practice, the 5HT1B and 1D receptors have more of the activity of vasoconstriction versus Lasmitan only has the 5HT1F receptor agonist activity.

So it's going to generally avoid vasoconstriction.

Now where that comes into play is we've got lots of warnings and contraindications

for patients who are at risk for cardiovascular disease or high risk for cardiovascular

...